Income Taxes (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended		9 Months Ended				3 Months Ended	9 Months Ended			3 Months Ended
	Jun. 27, 2014	Jun. 28, 2013	Jun. 27, 2014	Jun. 28, 2013	Mar. 28, 2014	Sep. 27, 2013	Jun. 27, 2014 Cadence Pharmaceuticals, Inc.	Jun. 27, 2014 Cadence Pharmaceuticals, Inc.	Mar. 19, 2014 Cadence Pharmaceuticals, Inc.	Mar. 19, 2014 Completed Technology Ofirmev Cadence Pharmaceuticals, Inc.	Jun. 27, 2014 Internal Revenue Service (IRS)
Income Taxes [Line Items]
Provision for (benefit from) income taxes	$ (2.4)	$ 19.8	$ (6.1)	$ 55.9
Income (loss) from continuing operations before income taxes	(26.7)	(7.9)	27.7	82.5
Tax benefit on special items	0.4	1.7	1.5	3.0			11.2	32.3
Separation costs	1.8	44.2	6.6	70.6
Deferred tax liability, net increase due to acquisition									296.4
Deferred tax liabilities, acquired intangible asset										499.6
Deferred tax assets, acquired NOLs									196.2
Deferred tax asset, acquired federal and state tax credits									5.8
Deferred tax assets, acquired valuation allowance									7.3
Unrecognized tax benefits	111.2		111.2			100.1
Unrecognized tax benefits, net increase			11.1
Unrecognized tax benefits, additions related to prior period tax positions			20.4
Unrecognized tax benefits, additions related to current year tax positions			0.7
Unrecognized tax benefits, decrease related to settlements			0.2
Unrecognized tax benefits, lapse of statute of limitations			9.8
Unrecognized tax benefits, which if favorably settled would benefit the effective tax rate					96.6
Interest accrued on unrecognized tax benefits	54.8		54.8			62.1
Income tax examination taxes and interest											35.9
Income Tax Examination, Tax											27.3
Income Tax Examination, Interest Expense											8.6
Unrecognized tax benefits that would impact effective tax rate, upper bound of change	56.1		56.1
Income tax penalties and interest accrued that would impact effective tax rate, upper bound of change	$ 24.6		$ 24.6